Product Datasheet

B7-H1/PD-L1/CD274 Antibody (orb1806316)

Catalog Number	orb1806316
Category	Antibodies
Description	Anti-B7-H1 / PD-L1 / CD274 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Target	B7-H1 / PD-L1 / CD274
Clonality	Monoclonal
Conjugation	Unconjugated
Reactivity	Human, Monkey, Mouse
Concentration	Batch dependent
Buffer/Preservatives	100 mM Proline/Acetic acid 20mM Arginine pH 5.0
Purity	>95%
Purification	Protein A
UniProt ID	Q9NZQ7
MW	145 kDa
Tested applications	ELISA, FA, FACS, In vivo
Expression System	CHO
Endotoxins	0.001 EU/ug

Biorbyt Ltd.
7 Signet Court, Swann Road
Cambridge
CB5 8LA
United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: +44 (0)1223 859353 | Fax: +1 (415) 651-8558

Biorbyt LLC
68 TW Alexander Drive
Research Triangle Park
Durham
NC 27713-2847
United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: +1 (415) 906-5211 | Fax: +1 (415) 651-8558

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Note	For research use only
Expiration Date	12 months from date of receipt.



Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.



The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab)is more than 100% ;determined by SEC-HPLC.

Biorbyt Ltd.
7 Signet Court, Swann Road
Cambridge
CB5 8LA
United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: +44 (0)1223 859353 | Fax: +1 (415) 651-8558

Biorbyt LLC
68 TW Alexander Drive
Research Triangle Park
Durham
NC 27713-2847
United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: +1 (415) 906-5211 | Fax: +1 (415) 651-8558



Immobilized human PD L1 His at 2 μg/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab);EC50=0.005894μg/mL.



Human PD-L1 CHO-K cells were stained with Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC263=1.533 nM.



The endocytosis ratio atezolizumab by HCC827 increased with the increase of antibody concentration; and the Internalization Rate (%) reached 60% at antibody concentration of 0.5 nM.

Biorbyt Ltd.
7 Signet Court, Swann Road
Cambridge
CB5 8LA
United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: +44 (0)1223 859353 | Fax: +1 (415) 651-8558

Biorbyt LLC
68 TW Alexander Drive
Research Triangle Park
Durham
NC 27713-2847
United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: +1 (415) 906-5211 | Fax: +1 (415) 651-8558



Atezolizumab inhibited the tumor growth of MC38 on C57BL/6N mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 85.2% at 2 mpk at D35.

Biorbyt Ltd.
7 Signet Court, Swann Road
Cambridge
CB5 8LA
United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: +44 (0)1223 859353 | Fax: +1 (415) 651-8558

Biorbyt LLC
68 TW Alexander Drive
Research Triangle Park
Durham
NC 27713-2847
United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: +1 (415) 906-5211 | Fax: +1 (415) 651-8558